(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt - 2Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- 3EU waters down plans to end new petrol and diesel car sales by 2035
- 4Before trips to Mars, we need better protection from cosmic rays
- 5Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- First Alert: Light snow through this evening
- Language Learning Stages: Which One Gets Your Vote?
- AfD in Brandenburg takes back suit against the intelligence service
- Volcanic eruption led to the Black Death, new research suggests
- Best Veggie lover Dinner: What's Your Plant-Based Pick?
- This Week In Space podcast: Episode 192 — Space, 2026!
- Trump awarded 1st FIFA Peace Prize by Gianni Infantino at 2026 World Cup draw
- What is the Significant Tech Expertise to Master Today?
